Red blood cells (RBCs), on the other hand, have been noted to be particularly sensitive to blocking CD47 as it regulates RBC clearance, and anemia is a concern with anti-CD47 therapies, though this adverse event is reported to be managed clinically with little complication.381 Currently, magrolimab is slated for five clinical trials, one in lymphoma, one in mycosis fungoides, one in MDS, and two in R/R AML. Here, CD47 is linked to anemia (phenotype).